Better Health for All

Adaptive Biotechnologies' core business is dedicated to transforming disease diagnosis and treatment by leveraging the immune system, with its entire product portfolio focused on health improvement. Its clonoSEQ product is FDA-cleared for detecting and monitoring measurable residual disease (MRD) in multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and Mantle Cell Lymphoma.

clonoSEQ has an industry-leading sensitivity of 1 in 1,000,000 cells, and patient surveys indicate 96% find MRD testing useful, with 78% reporting it informs treatment decisions. The company also launched T-Detect COVID to detect prior coronavirus infections and is developing therapies for cancer and autoimmune diseases. The company demonstrates a strong commitment to health innovation, investing in R&D for new products and therapies, including a collaboration with Genentech for TCR-based cell therapies with potential payments exceeding $2 billion. During the COVID-19 pandemic, Adaptive launched T-Detect COVID and contributed to SARS-CoV-2 vaccine development. Adaptive ensures price accessibility through its Adaptive Assist program, providing financial assistance to qualified uninsured and under-insured patients, resulting in 90% having no out-of-pocket costs for clonoSEQ. Payer coverage for clonoSEQ extends to hundreds of millions of lives across various cancers, including all Medicare patients with Mantle Cell Lymphoma. The company maintains comprehensive data privacy and protection policies, complying with all applicable laws, and requires Head of Privacy approval for re-identifying de-identified data. It adheres to Good Clinical Practices for its products, which are used in 143 active clinical trials. Adaptive provides a 24/7 anonymous hotline for reporting concerns and includes a "Risk Factors" section in its annual report. The company also invests in healthcare education for professionals and patients and supports preventative health measures through early disease detection diagnostics and participation in initiatives like Obliteride. No significant negative health externalities or mental health initiatives beyond internal employee support are reported.

Fair Money & Economic Opportunity

Adaptive Biotechnologies Corporation is a biotechnology company focused on developing and providing medical diagnostic tests and services. The ethical value 'Fair Money & Economic Opportunity' specifically evaluates financial institutions and their activities related to lending, insuring, moving, or storing money. The provided articles describe the company's clonoSEQ test, its Medicare pricing, and a patient support program (Adaptive Assist™) designed to help patients with insurance and billing for medical tests.

This program offers financial assistance for medical costs, but it does not constitute lending, insurance, or other financial services as defined by the value. As the company does not operate in the financial services sector, and no article provides specific, concrete data points relevant to any of the KPIs under this value, all KPIs must be omitted.

Fair Pay & Worker Respect

Adaptive Biotechnologies Corporation reported a CEO pay ratio of 29:1 for the 2024 fiscal year, with the CEO's compensation at $4,973,301 and the median employee pay at $170,306.

Employee engagement, based on Glassdoor reviews, shows an average rating of 3.4 out of 5 stars from 230 reviews. This rating is in line with the industry average of 3.5 stars for Pharmaceutical & Biotechnology.

Fair Trade & Ethical Sourcing

No specific, quantitative evidence was found in the provided articles for any of the Fair Trade & Ethical Sourcing KPIs. While Adaptive Biotechnologies has a Supplier Code of Conduct,

effective February 2023, which prohibits forced and child labor and requires suppliers to report violations within two business days, and also mentions a Supplier Diversity Program, there is no quantitative data on fair-trade certification share, audit frequency, actual forced or child labor incidents, supply chain traceability, remediation speed for the company, ethical clause coverage in contracts, high-risk materials spend, or supplier diversity spend.

Honest & Fair Business

The company has a Code of Conduct applicable to all employees, officers, and directors, which explicitly forbids retaliation against employees for reporting in good faith.

An anonymous hotline, managed by an independent third party, is available 24 hours a day, 7 days a week, 365 days a year. However, there is no explicit evidence provided regarding independent investigation processes for reports. No financial restatements were mentioned in the provided documents, and the CEO and CFO certified the accuracy and compliance of the Form 10-Q report with relevant acts. The company's annual report for the year ended December 31, 2024, filed on March 3, 2025, contained audited consolidated financial statements, but the financial statements for the period ending September 30, 2025, were unaudited.

Kind to Animals

The company's Supplier Code of Conduct, effective February 2023, states that suppliers shall treat animals humanely with pain and stress minimized.

It also mandates that if animal testing is required, it should be performed after consideration to replace animals, reduce the number of animals used, or refine procedures to minimize distress. Suppliers are required to report any violation of this Code of Conduct within two business days.

Planet-Friendly Business

The company's Supplier Code of Conduct, effective February 2023, requires suppliers to comply with all applicable environmental regulations, obtain necessary permits, and follow operational and reporting requirements.

Suppliers must also have systems to manage waste, air emissions, wastewater discharges, and prevent spills. Any violation of this code must be reported to Adaptive within two business days. The company's headquarters is home to approximately 100,000 bees in two hives, and it has rooftop plant beds with drip irrigation for a company garden, with workshops planned to educate employees about bees and biodiversity.

Safe & Smart Tech

The company explicitly states compliance with HIPAA, GDPR, and CCPA, indicating a good compliance program with applicable regulations.

Data retention is based on fulfilling purposes or legal requirements, which suggests some data minimization efforts but lacks specific short retention periods or strict necessity tests. Users have moderate control over their data, with options to opt out of marketing communications and request access, amendment, or deletion of their data via a portal or email. The company holds SOC 2 Type II certification, which is a recognized security and privacy certification, aligning with a standard approach to compliance.